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Abstract 
Background: Osteoporosis and migraine are both important public health problems and may have overlapping 
pathophysiological mechanisms. The aim of this study was to use a Taiwanese population‑based dataset to assess 
migraine risk in osteoporosis patients.
Methods: The Taiwan National Health Insurance Research Database was used to analyse data for 40,672 patients 
aged ≥20 years who had been diagnosed with osteoporosis during 1996–2010. An additional 40,672 age‑matched 
patients without osteoporosis were randomly selected as the non‑osteoporosis group. The relationship between 
osteoporosis and migraine risk was estimated using Cox proportional hazard regression models.
Results: During the follow‑up period, 1110 patients with osteoporosis and 750 patients without osteoporosis devel‑
oped migraine. After controlling for covariates, the overall incidence of migraine was 1.37‑fold higher in the osteopo‑
rosis group than in the non‑osteoporosis group (3.72 vs. 1.24 per 1000 person‑years, respectively). Migraine risk factors 
included high Charlson Comorbidity Index score, female gender, hypertension, depression, asthma, allergic rhinitis, 
obesity, and tobacco use disorder.
Conclusions: Our results indicate that patients with a history of osteoporosis had a higher risk of migraine.
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Background
Both osteoporosis and migraine are common conditions 
that can affect quality of life and can impose large social 
and economic burdens (Kuo et  al. 2015; Manandhar 
et al. 2015a, b; Mbewe et al. 2015; Rao et al. 2015; Steiner 
et al. 2015; Lampl et al. 2016). The National Institutes of 
Health Consensus Development Conference Statement 
defines osteoporosis as a skeletal disorder characterized 
by diminished bone strength resulting in increased frac-
ture risk. Bone strength is measured in terms of both 
bone mineral density (BMD) and bone quality (Nih Con-
sensus Development Panel on Osteoporosis Prevention 
and Therapy 2001). In elderly populations, osteoporosis 
affects approximately 30  % of women and 12  % of men 
(Rachner et  al. 2011). Migraine is a neurological disor-
der that manifests as a debilitating headache associated 
with altered sensory perception (Goadsby et  al. 2002; 
Charles 2013; Baykan et al. 2015; Manandhar et al. 2015a, 
b). The International Headache Society defines migraine 
as a headache that lasts for 4–72 h and has at least two 
of the following characteristics: pulsating quality, unilat-
eral localization, moderate-to-severe pain intensity, and 
aggravation by movement (Headache Classification Sub-
committee of the International Headache 2004). Previous 
studies have identified interacting relationships among 
migraine, various sleep disorders, depression, psoriasis, 
restless legs syndrome and cardiovascular disease (Kel-
man and Rains 2005; Pompili et  al. 2009; Schurks et  al. 
2009; Cho et al. 2015; Egeberg et al. 2015; Kim et al. 2016; 
Risal et  al. 2016). Migraine is associated with episodes 
of local sterile meningealinflammation, hypersensitized 
pain pathways, and increased inflammatory cytokines 
that contribute to the pathogenesis of osteoporosis, such 
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as interleukins (ILs) or tumor necrosis factor-α (Braun 
and Schett 2012; Egeberg et  al. 2015). Like osteoporo-
sis and other inflammatory conditions, migraine is also 
apparently associated with systemic endothelial dysfunc-
tion (Vanmolkot et  al. 2007; Sacco et  al. 2013; Steyers 
and Miller 2014). Although no recent studies have sug-
gested a link between osteoporosis and migraine, both 
conditions are independent risk factors for cardiovascu-
lar disease (Sumino et  al. 2008; Bigal et  al. 2010; Hyder 
et al. 2010), and both are comorbid with pain-related and 
psychiatric conditions (Kalaydjian and Merikangas 2008; 
Radaei et al. 2014). We therefore investigated the impact 




This population-based cohort study used data obtained 
from the Taiwan National Health Insurance Research 
Database (NHIRD) maintained by the national health 
care system of Taiwan. The NHIRD is an encrypted sec-
ondary database containing medical data for approxi-
mately 99  % of the 23.74 million residents of Taiwan. 
The Taiwan national health insurance program allows 
researchers to access this database of administrative data 
for patients. The NHIRD files are composed of compre-
hensive use and enrollment information of the patients. 
Besides, under regulations of the Personal Electronic 
Data Protection Law of Taiwan, all citizens and hospi-
tal identities in the NHIRD database were decoded. This 
retrospective cohort study analysed 1996–2010 data con-
tained in a subset of the NHIRD, the Longitudinal Health 
Insurance Database 2010, which comprises data for 1 
million beneficiaries randomly sampled from the primary 
NHIRD. In this study, diseases were identified and clas-
sified according to the diagnostic codes of the Interna-
tional Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM).
Ethical approval
The study was performed in accordance with the Decla-
ration of Helsinki guidelines and was also evaluated and 
approved by the Institutional Review Board of Kaohsi-
ung Medical University Hospital (KMUHIRB-EXEMPT 
(II)-20160016).
Study population
The study cohort included 40,672 patients aged 20 years 
or older who had been diagnosed with osteoporosis 
(ICD-9-CM code 733.0) during 1996–2010. To maximize 
accuracy, the analysis was limited to patients who had a 
record of ≥2 osteoporosis diagnoses during ambulatory 
visits or ≥1 diagnoses during inpatient care, an ICD-9 
code assigned by an orthopaedist, and at least one BMD 
examination. The index date was defined as the date of 
the first clinical visit for osteoporosis. A migraine (ICD-
9-CM code 346) was defined as a history of two or more 
migraine diagnoses in ambulatory visits or one or more 
migraine diagnoses in inpatient care as well as a record 
of an ICD-9 code for migraine assigned by a neurolo-
gist. The date of diagnosis was defined as the date of the 
first diagnosis of osteoporosis. Matching control subjects 
were assigned an identical “pseudo date of diagnosis”, 
which was the date of diagnosis in matched cases. The 
exclusion criteria were diagnosis of migraine before or on 
the index date, incomplete information, and age younger 
than 20 years.
The ratio of osteoporosis to non-osteoporosis patients 
was kept at 1:1 to enhance the power of statistical tests 
and to obtain a sufficient number of migraine cases for 
stratified analyses. The patients in the non-osteoporo-
sis cohort were selected by a simple random sampling 
method in which one insured patient without osteo-
porosis was randomly selected and frequency matched 
with each person in the osteoporosis cohort in the same 
period by age, gender, and year of osteoporosis diagno-
sis. A post hoc sample size was calculated to determine 
statistical power. Logistic regression analysis was used to 
obtain a 4-digit match of the propensity score for each 
patient with the covariates, including age and gender. As 
a result, 40,672 subjects were enrolled in the non-osteo-
porosis cohort. Figure  1 shows a flowchart of the study 
procedure.
Outcome and comorbidities
The patients in both the osteoporosis and non-osteo-
porosis cohorts were followed up until diagnosis with 
Fig. 1 Flow diagram of the present study from the National Health 
Insurance Research Database in Taiwan. LHID longitudinal Health 
Insurance Database
Page 3 of 8Wu et al. SpringerPlus  (2016) 5:1378 
migraine, withdrawal from insurance, or the end of 2010, 
whichever occurred first. Baseline comorbidities iden-
tified by ICD-9-CM codes in the claims records before 
the index date included hypertension (ICD-9-CM codes 
401-405), diabetes mellitus (ICD-9-CM code 250), hyper-
lipidemia (ICD-9-CM code 272), depression (ICD-9-CM 
codes 296.2, 296.3, 300.4 and 311), asthma (ICD-9-CM 
code 493), allergic rhinitis (ICD-9-CM code 477), pso-
riasis (ICD-9-CM code 696.1), obesity (ICD-9-CM code 
278), tobacco use disorder (ICD-9-CM code 350.1), and 
alcohol attributed disease (ICD-9-CM codes 291.0-9, 
303, 305.0, 357.5, 425.5, 535.3, 571.0-3, 980.0 and V11.3). 
The Charlson Comorbidity Index (CCI) score was used 
to assess the severity of comorbidities, i.e., myocardial 
infarction, congestive heart failure, peripheral vascular 
disease, cerebrovascular disease, dementia, chronic pul-
monary disease, rheumatic disease, peptic ulcer disease, 
liver disease (mild, moderate, or severe), diabetes (with 
or without chronic complication), hemiplegia or paraple-
gia, renal disease, any malignancy (including lymphoma 
and leukemia but excluding skin malignancy), metastatic 
solid tumor, human immunodeficiency virus infection 
and acquired immune deficiency syndrome. The CCI 
scores were then categorized into four levels: 0, 1–2, 3–4 
and ≥5.
Statistical analyses
Chi square test was used to compare distributions of 
categorical demographics and clinical characteristics 
between the osteoporosis and non-osteoporosis cohorts. 
The Student t test and Wilcoxon rank-sum test were 
used as appropriate to compare mean age and follow-
up time (y) between the two cohorts. The Kaplan–Meier 
method was used to estimate cumulative incidence, 
and the differences between the curves were tested by 
2-tailed log-rank test. For osteoporosis patients, survival 
was calculated until hospitalization, an ambulatory visit 
for migraine, or the end of the study period (December 
31, 2010), whichever occurred first. Incidence rates of 
migraine estimated in 1000 person-years were compared 
between the two cohorts. Univariable and multivari-
able Cox proportional hazard regression models were 
used to calculate hazard ratios (HRs) and 95  % confi-
dence intervals (CIs) for migraine if the proportional 
hazards assumption was satisfied. The multivariable Cox 
models were adjusted for age, gender, CCI score, and 
relevant comorbidities. A 2-tailed P value of <0.05 was 
considered statistically significant. All data processing 
and statistical analyses were performed using Statistical 
Analysis Software, version 9.4 (SAS Institute, Cary, NC, 
USA).
Results
Baseline characteristics of patients with and 
without osteoporosis
The baseline demographic characteristics and comorbid-
ities in the two cohorts are presented in Table  1. In the 
osteoporosis cohort, 82.48 % patients were female. Com-
pared to the non-osteoporosis cohort, the osteoporosis 
cohort had significantly higher percentages of patients 
with hypertension (70.12 vs. 54.07, P  <  0.001), diabe-
tes mellitus (38.58 vs. 27.71, P  <  0.001), hyperlipidemia 
(61.28 vs. 43.96, P  <  0.001), depression (21.21 vs. 11.71, 
P < 0.001), asthma (28.77 vs. 19.20, P < 0.001), allergic rhi-
nitis (44.62 vs. 32.38, P < 0.001), psoriasis (2.15 vs. 1.43, 
P < 0.001), obesity (2.64 vs. 2.11, P < 0.001), tobacco use 
disorder (1.91 vs. 1.04, P < 0.001) and alcohol-attributable 
disease (2.63 vs. 1.92, P < 0.001). The osteoporosis cohort 
also had higher CCI scores. During a median observa-
tion time of 3.5  years, 2.73  % (1110) of the osteoporosis 
patients had migraine (interquartile range [IQR] 1.5–6.2). 
The migraine incidence of osteoporosis cohort was sig-
nificantly (P  <  0.001) higher than that in the non-osteo-
porosis patients (751 with migraine out of 40,672 age- and 
gender-matched controls [1.85  %]) during a median 
observation time of 7.2  years [IQR 4.8–10.5]). Migraine 
development was significantly faster in the osteoporo-
sis group (3.5  years) compared to the non-osteoporosis 
group (7.2 years) for the respective observation periods.
Migraine incidence and risk
The migraine incidence and HRs by gender, age and 
comorbidity are stratified in Table 2. During the follow-up 
period, migraine developed in 2.73 % (1110) of the osteopo-
rosis patients and in 1.85 % (750) of the non-osteoporosis 
patients. The overall migraine risk was 1.37 times greater in 
the osteoporosis group compared to the non-osteoporosis 
group (3.72 vs. 1.24 per 1000 person-years, respectively) 
after adjusting for age, gender, CCI, and related comor-
bidities (hypertension, diabetes mellitus, hyperlipidemia, 
depression, asthma, allergic rhinitis, psoriasis, obesity, 
tobacco use disorder and alcohol-attributable disease).
The gender-specific analyses showed that, in both 
cohorts, the incidence of osteoporosis was higher in 
women than in men (3.61 vs. 2.28 per 1000 person-years, 
respectively, in the osteoporosis cohort; 1.35 vs. 0.73 per 
1000 person-years, respectively, in the non-osteoporosis 
cohort). Additionally, the osteoporosis group had a sig-
nificantly higher migraine risk in both genders (adjusted 
HR 1.34, 95 % CI 1.19–1.49 for women; adjusted HR 1.66, 
95 % CI 1.19–2.31 for men).
Although the incidence of migraine was consistently 
higher in all age groups in the osteoporosis cohort 
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compared to the non-osteoporosis cohort, the migraine 
risk decreased with age. Age-specific risk compari-
sons showed that, compared to the non-osteoporosis 
cohort, the osteoporosis cohort had a significantly 
higher migraine risk in patients under 50  years old 
(adjusted HR 1.46, 95  % CI 1.17–1.82, P  <  0.001) than 
in patients over 50  years old (HR 1.34, 95  % CI 1.20–
1.50, P  <  0.001). Regardless of comorbidities, migraine 
risk was higher in osteoporosis patients than in non-
osteoporosis patients. However, the migraine risk con-
tributed by osteoporosis decreased in the presence of 
comorbidity.
The Kaplan–Meier curves for the cumulative incidence 
of migraine between the osteoporosis and non-osteopo-
rosis groups at the 15-year follow up are compared in 
Fig.  2. The Kaplan–Meier curves showed a significantly 
higher cumulative incidence of migraine in the osteopo-
rosis cohort compared to the non-osteoporosis cohort 
(log-rank test P < 0.001).
Risks factors for migraine in osteoporosis patients
The Cox regression analysis revealed the following risk 
factors for migraine in the osteoporosis group: high CCI 
score, female gender, hypertension, depression, asthma, 
allergic rhinitis, obesity, and tobacco use disorder. Risk 
factors for migraine were female gender (adjusted HR 
1.51, 95 % CI 1.23–1.85), hypertension (adjusted HR 1.19, 
95 % CI 1.02–1.38), depression (adjusted HR 2.36, 95 % 
CI 2.09–2.66), asthma (adjusted HR 1.28, 95 % CI 1.13–
1.45), allergic rhinitis (adjusted HR 1.46, 95  % CI 1.29–
1.66), obesity (adjusted HR 1.79, 95  % CI 1.40–2.28), 
tobacco use disorder (adjusted HR 2.30, 95  % CI 1.78–
2.97) and high CCI (adjusted HR 1.57, 95 % CI 1.44–1.71) 
(Table 3).
Discussion
To our knowledge, this is the first nationwide population-
based study of the relationship between osteoporosis and 
subsequent migraine in an Asian population. During the 
Table 1 Baseline characteristics of patients with and without osteoporosis
IQR interquartile range, SD standard deviation
Variables Osteoporosis P value
Yes (N = 40,672) No (N = 40,672)
Migraine patients, n (%) 1110 (2.73) 751 (1.85) <0.001
Period of developing migraine, median (IQR), years 3.5 (1.5–6.2) 7.2 (4.8–10.5) <0.001
Mean age at diagnosis of migraine, years 57.9 (10.4) 62.6 (10.3) <0.001
Age group, n (%)
 20–49 7361 (18.10) 7361 (18.10)
 ≥50 33,311 (81.90) 33,311 (81.90) 1.000
Gender, n (%)
 Men 7125 (17.52) 7125 (17.52)
 Women 33,547 (82.48) 33,547 (82.48) 1.000
Charlson Comorbidity Index, n  (%)
 0 1912 (4.70) 7744 (19.04)
 1–2 9667 (23.77) 14,437 (35.50)
 3–4 11,911 (29.29) 9861 (24.25)
 ≥5 17,182 (42.25) 8630 (21.22) <0.001
Co‑morbidity, n (%)
 Hypertension 28,521 (70.12) 21,991 (54.07) <0.001
 Diabetes mellitus 15,693 (38.58) 11,272 (27.71) <0.001
 Hyperlipidemia 24,923 (61.28) 17,879 (43.96) <0.001
 Depression 8625 (21.21) 4764 (11.71) <0.001
 Asthma 11,700 (28.77) 7807 (19.20) <0.001
 Allergic rhinitis 18,146 (44.62) 13,168 (32.38) <0.001
 Psoriasis 874 (2.15) 583 (1.43) <0.001
 Obesity 1073 (2.64) 857 (2.11) <0.001
 Tobacco use disorder 776 (1.91) 422 (1.04) <0.001
 Alcohol attributed disease 1069 (2.63) 780 (1.92) <0.001
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follow-up period, migraine developed in 2.73  % (1110) 
patients with osteoporosis and in 1.85  % (750) patients 
without osteoporosis. After controlling for potential 
confounding factors, migraine risk was 1.37-fold higher 
in the osteoporosis group than in the non-osteoporosis 
group. Patients with osteoporosis, particularly those with 
high CCI score, female gender, hypertension, depression, 
asthma, allergic rhinitis, obesity, and tobacco use disor-
der, had a high migraine risk.
The exact mechanisms underlying the relationship 
between migraine and osteoporosis are likely to be elu-
sive. However, several lines of evidence in the literature 
suggest that osteoporosis and migraine have a shared 
pathophysiology. First, bone density is significantly asso-
ciated with magnesium, an essential micronutrient with a 
wide range of metabolic, structural and regulatory func-
tions (Jahnen-Dechent and Ketteler 2012). In humans, 
magnesium deficiency contributes to osteoporosis. Low 
serum magnesium is a co-contributing factor in osteope-
nia in adults with sickle cell anemia (Elshal et  al. 2012). 
Moreover, an association between serum magnesium 
and bone density has been identified in pre- and post-
menopausal women (Saito et al. 2004; Song et al. 2007). 
Magnesium deficiency also has a strong association 
with migraine attacks (Welch and Ramadan 1995). Gal-
lai et al. showed that individuals suffering from migraine 
Table 2 Incidence and hazard ratios of migraine by demographic characteristics and comorbidity among patients with or 
without osteoporosis
PYs person-years, Rate incidence rate in per 1000 person-years, 95 % CI 95 % confidence interval, HR hazard ratio
a Model adjusted for age, gender, Charlson Comorbidity Index and relevant comorbidities (hypertension, diabetes mellitus, hyperlipidemia, depression, asthma, 
allergic rhinitis, psoriasis, obesity, tobacco use disorder and alcohol attributed disease)
b Patients with any examined comorbidities, including hypertension, diabetes mellitus, hyperlipidemia, depression, asthma, allergic rhinitis, psoriasis, obesity, tobacco 





Variables Patients with osteoporosis Patients without osteoporosis Compared to non- osteoporosis
Migraine PYs Rate Migraine PYs Rate CrudeHRa (95 % CI) Adjusted HRa (95 % 
CI)
Overall 1110 324,126.20 3.42 751 604,550.99 1.24 2.48 (2.25–2.73)c 1.37 (1.23–1.51)c
Gender
 Men 104 45,604.93 2.28 78 106,313.43 0.73 2.80 (2.04–3.85)c 1.66 (1.19–2.31)d
 Women 1006 278,521.27 3.61 573 498,237.56 1.35 2.39 (2.17–2.66)c 1.34 (1.19–1.49)c
Stratify by age
 20–49 252 64,474.34 3.91 130 109,506.02 1.19 2.97 (2.39–3.68)c 1.46 (1.17–1.82)c
 ≥50 858 259,651.83 3.30 621 495,044.97 1.25 2.37 (2.12–2.64)c 1.34 (1.20–1.50)c
Comorbidityb
 No 19 20,949.87 0.91 43 127,923.68 0.34 2.41 (1.40–4.14)e 1.78 (1.03–3.06)f
 Yes 1091 303,176.33 3.59 708 476,627.31 1.49 2.18 (1.97–2.41)c 1.34 (1.22–1.49)c
Fig. 2 Cumulative incidence of migraine for adult patients with osteoporosis and the general population control cohort
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headaches had lower plasma and saliva magnesium lev-
els between the attacks compared to controls without 
migraine headaches (Gallai et al. 1992). Both osteoporo-
sis and migraine are associated with hypomagnesemia, 
which suggests an interplay between osteoporosis and 
migraine. Second, the relationship between migraine and 
osteoporosis might be explained at least partly by their 
common inflammatory mediators. Neurogenic inflam-
mation resulting from activation of the trigeminal vas-
cular system is the main cause of the pain produced by 
migraine. Stimulation of trigeminal ganglion nociceptors 
induces the release of proinflammatory substances, par-
ticularly calcitonin gene-related peptide (CGRP) (Silber-
stein 2004; Dalkara et al. 2006; D’Andrea and Leon 2010). 
Individuals with osteoporosis also had elevated CGRP 
levels (Lin et al. 2001). Experimental injections of CGRP 
into eviratated rats indicate that CGRP may also affect 
the release of osteoblastic cytokines and may indi-rectly 
regulate the suppressed bone resorption of osteoclasts 
(Valentijn et  al. 1997). Inflammatory cytokines associ-
ated with osteoporosis such as tumor necrosis factor-
αand IL-6 (Braun and Schett 2012; Wiseman et al. 2014) 
are elevated at the onset of migraine attacks (Perini et al. 
2005). Finally, C-reactive protein, which increases dur-
ing systemic inflammation, is elevated in both osteopo-
rosis and migraine (Vanmolkot and de Hoon 2007; de 
Pablo et  al. 2012). Thus, the inflammatory state caused 
by osteoporosis may increase the frequency or severity 
of migraine headaches by exacerbating the inflammatory 
response.
The strength of our study is the use of a large sample 
that is highly representative of the general population 
and provides sufficient statistical power to identify an 
association between osteoporosis and migraine risk. 
However, several limitations must be considered when 
interpreting these findings. One limitation is that the 
analysis only included observational data, i.e., ICD-
9-CM codes, the accuracy of which depends on the 
clinical performance of individual physicians. That 
is, the accuracy of diagnostic codes in the database is 
a potential limitation. Notably, however, the Taiwan 
National Health Insurance program requires all insur-
ance claims to be reviewed and audited by medical 
reimbursement specialists in the Bureau of National 
Health Insurance, which supports the validity and accu-
racy of the observed associations between osteoporosis 
and migraine. Furthermore, many studies have already 
used the NHIRD database because of its large size and 
long follow-up period (Chiu et al. 2015; Chu et al. 2015; 
Wu et  al. 2015, 2016a, b, c, d). A second limitation is 
that the NHIRD does not contain detailed data that 
can be used to identify osteoporosis risk factors such 
as exercise capacity, body mass index, smoking, alcohol 
consumption, and dietary habits. A third limitation is 
that the Taiwan population analysed in this study was 
mostly of Chinese descent. Therefore, caution is needed 
when extrapolating the results to other ethnic groups; 
further studies are needed to determine whether these 
findings can be generalized to other ethnicities. Finally, 
this retrospective cohort study may have been biased 
by unrecognized or unadjusted confounding variables, 
despite the use of statistical methods for reducing their 
confounding effects.
Conclusions
In summary, this nationwide population-based cohort 
study revealed that adult patients with osteoporosis 
had a significantly higher risk of developing subsequent 
migraine compared to controls without osteoporosis. 
Clinicians should be aware that osteoporosis is a poten-
tial risk factor for migraine. Further studies are recom-
mended to confirm this association and to explore its 
mechanisms.
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